MaxCyte Net Income
| MXCT Stock | USD 0.79 0.02 2.47% |
As of the 9th of February, MaxCyte secures the Mean Deviation of 3.16, risk adjusted performance of (0.19), and Standard Deviation of 3.92. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of MaxCyte, as well as the relationship between them.
MaxCyte Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 1.7783 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -36.9 M | -35.1 M | |
| Net Loss | -36.9 M | -35.1 M | |
| Net Loss | -21.2 M | -22.3 M | |
| Net Loss | (0.35) | (0.37) |
MaxCyte | Net Income | Build AI portfolio with MaxCyte Stock |
The evolution of Net Income for MaxCyte provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how MaxCyte compares to historical norms and industry peers.
Latest MaxCyte's Net Income Growth Pattern
Below is the plot of the Net Income of MaxCyte over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in MaxCyte financial statement analysis. It represents the amount of money remaining after all of MaxCyte operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is MaxCyte's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in MaxCyte's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (41.05 M) | 10 Years Trend |
|
Net Income |
| Timeline |
MaxCyte Net Income Regression Statistics
| Arithmetic Mean | (14,748,925) | |
| Coefficient Of Variation | (99.64) | |
| Mean Deviation | 12,375,197 | |
| Median | (9,917,000) | |
| Standard Deviation | 14,695,104 | |
| Sample Variance | 215.9T | |
| Range | 40.1M | |
| R-Value | (0.92) | |
| Mean Square Error | 36.7T | |
| R-Squared | 0.84 | |
| Slope | (2,668,201) | |
| Total Sum of Squares | 3455.1T |
MaxCyte Net Income History
Other Fundumenentals of MaxCyte
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
MaxCyte Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for MaxCyte is extremely important. It helps to project a fair market value of MaxCyte Stock properly, considering its historical fundamentals such as Net Income. Since MaxCyte's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of MaxCyte's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of MaxCyte's interrelated accounts and indicators.
Click cells to compare fundamentals
Is there potential for Health Care Equipment & Supplies market expansion? Will MaxCyte introduce new products? Factors like these will boost the valuation of MaxCyte. Expected growth trajectory for MaxCyte significantly influences the price investors are willing to assign. Understanding fair value requires weighing current performance against future potential. All the valuation information about MaxCyte listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.43) | Revenue Per Share | Quarterly Revenue Growth (0.16) | Return On Assets | Return On Equity |
Understanding MaxCyte requires distinguishing between market price and book value, where the latter reflects MaxCyte's accounting equity. The concept of intrinsic value - what MaxCyte's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Market sentiment, economic cycles, and investor behavior can push MaxCyte's price substantially above or below its fundamental value.
Understanding that MaxCyte's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether MaxCyte represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, MaxCyte's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
MaxCyte 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to MaxCyte's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of MaxCyte.
| 11/11/2025 |
| 02/09/2026 |
If you would invest 0.00 in MaxCyte on November 11, 2025 and sell it all today you would earn a total of 0.00 from holding MaxCyte or generate 0.0% return on investment in MaxCyte over 90 days. MaxCyte is related to or competes with Profound Medical, TriSalus Life, Anteris Technologies, LENSAR, Owlet, Perspective Therapeutics, and Prenetics Global. MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-gene... More
MaxCyte Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure MaxCyte's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess MaxCyte upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.27) | |||
| Maximum Drawdown | 15.87 | |||
| Value At Risk | (7.14) | |||
| Potential Upside | 5.44 |
MaxCyte Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for MaxCyte's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as MaxCyte's standard deviation. In reality, there are many statistical measures that can use MaxCyte historical prices to predict the future MaxCyte's volatility.| Risk Adjusted Performance | (0.19) | |||
| Jensen Alpha | (1.10) | |||
| Total Risk Alpha | (1.36) | |||
| Treynor Ratio | (0.58) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of MaxCyte's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
MaxCyte February 9, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.19) | |||
| Market Risk Adjusted Performance | (0.57) | |||
| Mean Deviation | 3.16 | |||
| Coefficient Of Variation | (409.36) | |||
| Standard Deviation | 3.92 | |||
| Variance | 15.4 | |||
| Information Ratio | (0.27) | |||
| Jensen Alpha | (1.10) | |||
| Total Risk Alpha | (1.36) | |||
| Treynor Ratio | (0.58) | |||
| Maximum Drawdown | 15.87 | |||
| Value At Risk | (7.14) | |||
| Potential Upside | 5.44 | |||
| Skewness | (0.09) | |||
| Kurtosis | 0.0127 |
MaxCyte Backtested Returns
MaxCyte has Sharpe Ratio of -0.27, which conveys that the firm had a -0.27 % return per unit of risk over the last 3 months. MaxCyte exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please verify MaxCyte's Standard Deviation of 3.92, mean deviation of 3.16, and Risk Adjusted Performance of (0.19) to check out the risk estimate we provide. The company secures a Beta (Market Risk) of 1.67, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, MaxCyte will likely underperform. At this point, MaxCyte has a negative expected return of -0.98%. Please make sure to verify MaxCyte's potential upside and rate of daily change , to decide if MaxCyte performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.46 |
Average predictability
MaxCyte has average predictability. Overlapping area represents the amount of predictability between MaxCyte time series from 11th of November 2025 to 26th of December 2025 and 26th of December 2025 to 9th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of MaxCyte price movement. The serial correlation of 0.46 indicates that about 46.0% of current MaxCyte price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.46 | |
| Spearman Rank Test | 0.38 | |
| Residual Average | 0.0 | |
| Price Variance | 0.08 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, MaxCyte reported net income of (41.05 Million). This is 112.03% lower than that of the Health Care Equipment & Supplies sector and 117.24% lower than that of the Health Care industry. The net income for all United States stocks is 107.19% higher than that of the company.
MaxCyte Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses MaxCyte's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of MaxCyte could also be used in its relative valuation, which is a method of valuing MaxCyte by comparing valuation metrics of similar companies.MaxCyte is currently under evaluation in net income category among its peers.
MaxCyte Institutional Holders
Institutional Holdings refers to the ownership stake in MaxCyte that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of MaxCyte's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing MaxCyte's value.| Shares | Dimensional Fund Advisors, Inc. | 2025-06-30 | 1.7 M | Chevy Chase Trust Holdings, Inc. | 2025-06-30 | 1.7 M | Silvercrest Asset Management Group Llc | 2025-06-30 | 1.1 M | Citadel Advisors Llc | 2025-06-30 | 1 M | Northern Trust Corp | 2025-06-30 | 785.8 K | Renaissance Technologies Corp | 2025-06-30 | 717.8 K | Royce & Associates, Lp | 2025-06-30 | 657.1 K | Goldman Sachs Group Inc | 2025-06-30 | 442.6 K | Rice Hall James & Associates, Llc | 2025-06-30 | 417.8 K | Blackrock Inc | 2025-06-30 | 10.2 M | Cadian Capital Management Lp | 2025-06-30 | 8.9 M |
MaxCyte Fundamentals
| Return On Equity | -0.23 | ||||
| Return On Asset | -0.14 | ||||
| Profit Margin | (1.33) % | ||||
| Operating Margin | (1.62) % | ||||
| Current Valuation | (1.37 M) | ||||
| Shares Outstanding | 106.67 M | ||||
| Shares Owned By Insiders | 1.70 % | ||||
| Shares Owned By Institutions | 82.29 % | ||||
| Number Of Shares Shorted | 2.5 M | ||||
| Price To Book | 0.48 X | ||||
| Price To Sales | 2.50 X | ||||
| Revenue | 38.63 M | ||||
| Gross Profit | 27.53 M | ||||
| EBITDA | (46.41 M) | ||||
| Net Income | (41.05 M) | ||||
| Cash And Equivalents | 240.89 M | ||||
| Cash Per Share | 2.37 X | ||||
| Total Debt | 18.03 M | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 14.24 X | ||||
| Book Value Per Share | 1.69 X | ||||
| Cash Flow From Operations | (27.61 M) | ||||
| Short Ratio | 3.87 X | ||||
| Earnings Per Share | (0.43) X | ||||
| Target Price | 6.07 | ||||
| Number Of Employees | 114 | ||||
| Beta | 1.3 | ||||
| Market Capitalization | 86.19 M | ||||
| Total Asset | 239.47 M | ||||
| Retained Earnings | (216.85 M) | ||||
| Working Capital | 155.91 M | ||||
| Net Asset | 239.47 M |
About MaxCyte Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze MaxCyte's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of MaxCyte using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of MaxCyte based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for MaxCyte Stock Analysis
When running MaxCyte's price analysis, check to measure MaxCyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MaxCyte is operating at the current time. Most of MaxCyte's value examination focuses on studying past and present price action to predict the probability of MaxCyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MaxCyte's price. Additionally, you may evaluate how the addition of MaxCyte to your portfolios can decrease your overall portfolio volatility.